Skip to main content
Fig. 1 | World Journal of Surgical Oncology

Fig. 1

From: Different clinical significance of FGFR1–4 expression between diffuse-type and intestinal-type gastric cancer

Fig. 1

Immunostaining for fibroblast growth factor receptor (FGFR)1, FGFR2, FGFR3, and FGFR4. Representative primary gastric carcinomas exhibiting high expression for (a) FGFR1, (b) FGFR2, (c) FGFR3, and (d) FGFR4 in diffuse-type gastric cancer. Representative primary gastric carcinomas exhibiting high expression for (e) FGFR1, (f) FGFR2, (g) FGFR3, and (h) FGFR4 in intestinal-type gastric cancer. Magnification, ×400

Back to article page